Formycon AG (WBO:FYB) Beta: N/A (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:FYB Formycon AG WBO:FYB
39 GF Score
Price €18.30
GF Value €37.37
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-16), Formycon AG's Beta is Not available.

Formycon AG  (WBO:FYB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Formycon AG Beta Related Terms

Formycon AG Beta Historical Data

* Premium members only.

The historical data trend for Formycon AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG Beta Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:FYB
39GF Score
Formycon AG WBO:FYB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Formycon AG (WBO:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.30 is trading 51% below its estimated GF Value™ of €37.37. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for WBO:FYB:

  • Beta: N/A
  • GF Value™: €37.37 vs. price of €18.30 (51% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Other Exchanges 0W4N:UKFYB:Germany
Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
39GF Score

Get the complete analysis for WBO:FYB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.30
Price
€37.37
GF Value